Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
This website uses cookies to enhance your browsing experience. By using this site, you agree to our use of cookies. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Please refer to the “External Data Transmission” section for further information.
